An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)

Trial Profile

An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Registrational
  • Acronyms SAPPHIRE
  • Sponsors Roche
  • Most Recent Events

    • 11 Oct 2016 Time frame of primary endpoint has been changed from Up to 24 months to Baseline up to 36 months.
    • 11 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.
    • 11 Oct 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top